Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 6
Submit an article Journal homepage
515
Views
90
CrossRef citations to date
0
Altmetric
Drug Evaluations

Sunitinib in solid tumors

Hui K Gan Princess Margaret Hospital, Division of Medical Oncology and Hematology, 610 University Avenue, Toronto, ON M5G 2M9, Canada +1 416 946 2399; +1 416 946 6546; [email protected]
, MD PhD,
Bostjan Seruga Princess Margaret Hospital, Division of Medical Oncology and Hematology, 610 University Avenue, Toronto, ON M5G 2M9, Canada +1 416 946 2399; +1 416 946 6546; [email protected]
, MD MSc &
Jennifer J Knox Princess Margaret Hospital, Division of Medical Oncology and Hematology, 610 University Avenue, Toronto, ON M5G 2M9, Canada +1 416 946 2399; +1 416 946 6546; [email protected]
, MD FRCPC MSc
Pages 821-834 | Published online: 20 May 2009

Bibliography

  • Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46(7):1116-9
  • Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
  • Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96
  • O'Farrell A-M, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101(9):3597-605
  • Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35
  • Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329-38
  • Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006;17(3):353-8
  • Izzedine H, Etienne-Grimaldi MC, Renee N, et al. Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 2009;20(1):190-2
  • Khosravan R, Toh M, LaFargue J, et al. Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis [abstract]. J Clin Oncol 2008;26(Suppl 15):2578
  • Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Translational Med 2007;5:32
  • Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13(9):2643-50
  • Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008;61(3):515-24
  • George S, Blay JY, Casali PG, et al. Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and pharmacodynamic analysis. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):10554
  • GLOBOCAN 2002. Available from: http://www-dep.iarc.fr/ [Cited 16th February 2009]
  • Kaelin WG Jr, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007;13(2 Pt 2):680s-684s
  • Cho D, Signoretti S, Regan M, et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13(2 Pt 2):758s-63s
  • Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007;177(1):346-52
  • Sourbier C, Lindner V, Lang H, et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 2006;66(10):5130-42
  • Gunaratnam L, Morley M, Franovic A, et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 2003;278(45):44966-74
  • Smith K, Gunaratnam L, Morley M, et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res 2005;65(12):5221-30
  • de Paulsen N, Brychzy A, Fournier MC, et al. Role of transforming growth factor-alpha in von Hippel–Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001;98(4):1387-92
  • Coppin C, Coppin C. Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Rev Anticancer Ther 2008;8(6):907-19
  • Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
  • Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
  • Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2008;370(9605):2103-11
  • Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
  • Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):5024
  • Heng DY, Elson P, Golshayan AR, et al. A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):16057-
  • Hariharan S, Szczylik C, Porta C, et al. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):5094
  • Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 2007;25(18s (Suppl):A5010
  • Plimack ER, Jonasch E, Bekele BN, et al. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): a phase II study. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):5112-
  • Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26(1):127-31
  • van der Veldt AA, Boven E, Helgason HH, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008;99(2):259-65
  • Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol 2008;34(8):844-50
  • Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279(5350):577-80
  • Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61(22):8118-21
  • Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299(5607):708-10
  • Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80
  • George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009; 11 March 2009 [Epub ahead of print]
  • Porta C, Szczylik C, Bracarda S, et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):5114
  • Uemura H, Shinohara N, Naito S, Akaza H. A phase II study of the efficacy and safety of sunitinib in treatment-naive and pretreated Japanese patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):16108
  • Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26(11):1810-6
  • Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26(4):650-6
  • Gallagher DJ, Milowsky MI, Gerst SR, et al. Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):5082
  • Kulke MH, Lenz H-J, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26(20):3403-10
  • Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):6025
  • Keohan ML, Morgan JA, D'Adamo DR, et al. Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: results of a phase II trial. J Clin Oncol (Meeting Abstracts) 2008;26 (15 Suppl):10533
  • Vigil CE, Chiappori AA, Williams CA, et al. Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):10535
  • Moehler M, Hartmann JT, Lordick F, et al. Sunitinib in patients with chemo-refractory metastatic gastric cancer: preliminary results of an open-label, prospective nonrandomized multicenter Aio phase II trial. ASCO Gastrointestinal Cancers Symposium, 15 – 17 January 2009, San Francisco, CA, USA: A61
  • Chan KR, Gundala S, Laudadio M, et al. A pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):9047-
  • Choong NW, Cohen EE, Kozloff MF, et al. Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):6064
  • O'Reilly EM, Niedzwiecki D, Hollis DR, et al. A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J Clin Oncol (Meeting Abstracts) 2008;26 (15 Suppl):4515
  • Winer E, Gralow J, Diller L, et al. Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention and Screening – A Report From the American Society of Clinical Oncology. J Clin Oncol 2009;27(5):812-26
  • Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
  • Zhu AX, Sahani DV, Di ToMASO, et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):4521
  • Saltz LB, Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007;25(30):4793-9
  • Starling N, Vazquez F, Cunningham D, et al. Phase I study to evaluate the safety and efficacy of sunitinib in combination with FOLFIRI in treatment-naive metastatic colorectal cancer (mCRC). J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):3563
  • Pfeiffer P, Jørgensen TL, Jensen BV, et al. Addition of sunitinib to biweekly cetuximab and irinotecan as salvage therapy in patients with metastatic colorectal cancer after failure to CetIri. ASCO Gastrointestinal Cancers Symposium, 15 - 17 January 2009, San Francisco, CA, USA: A401
  • Sweeney C, Verschraegen C, Chiorean G, et al. A phase I dose escalation study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2007;25 (18 Suppl):3592
  • Chiorean EG, Sweeney CJ, Verschraegen CF, et al. Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): a phase I dose-finding study. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):3562
  • Royce M, Chiorean EG, Sweeney C, et al. A phase I dose-finding study of sunitinib in combination with capecitabine in patients with advanced solid tumors. ASCO Breast Cancer Symposium 5 – 7 September 2008, Washington DC, USA: A169
  • Chow LQ, Jonker DJ, Laurie SA, et al. Sunitinib (SU) in combination with pemetrexed (P) in patients (pts) with advanced solid malignancies: a phase I dose escalation study. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):3566
  • Traynor AM, Sandler AB, Schiller JH, et al. Phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs). J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):3564
  • Brell JM, Bokar JA, Cooney MM, et al. Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. J Clin Oncol (Meeting Abstracts) 2008;26 (15 Suppl):13533
  • Michaelson MD, Schwarzberg A, Ryan DP, et al. A phase I dose-finding study of sunitinib (SU) in combination with gemcitabine (G) in patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2008;26 (15 Suppl):14522
  • Leong S, Eckhardt SG, Chan E, et al. A phase I study of sunitinib in combination with modified FOLFOX 6 (mFOLFOX6) chemotherapy. 2007 ASCO Gastrointestinal Cancers Symposium 2007:A285
  • Heath EI, Blumenschein GR, Jr COHEN, et al. Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs). J Clin Oncol (Meeting Abstracts) 2008;26 (15 Suppl):3565
  • Rugo HS, Lyandres J, Melisko M, et al. Phase I study of sunitinib (S) in combination with metronomic dosing of cyclophosphamide and methotrexate (CM) in patients with metastatic breast cancer (MBC). ASCO Breast Cancer Symposium 2008:A165
  • Mariani G, Cardoso F, Besse-Hammer T, et al. Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): an exploratory evaluation. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):14534
  • George DJ, Liu G, Wilding G, et al. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) – preliminary results. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):5131
  • Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009;94(1):5-9
  • Hahn NM, Reckova M, Cheng L, et al. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 2009;27(3):460-3
  • Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
  • Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 2007;25 (18S (Suppl):A5038
  • Sepulveda J, Maroto P, Andres R, et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):16100
  • Dudek AZ, Zolnierek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115(1):61-7
  • Rini BI, Hutson TE, Elson P, et al. A prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. 2008 ASCO Genitourinary Cancers Symposium 2008:A346
  • Whorf RC, Hainsworth JD, Spigel DR, et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 2008;26(20 Suppl):A5010
  • Eichelberg C, Heuer R, Chun FK, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008;54(6):1373-8
  • Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179(1):81-6; discussion 6
  • Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26(22):3743-8
  • Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36
  • Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009;32(2):181-5
  • Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21(1):99-101
  • Drucker B, Bacik J, Ginsberg M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21(3):341-5
  • Beeram M, Rowinsky EK, Weiss GR, et al. Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: a phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging. J Clin Oncol 2004;22(14S (Suppl):A3050
  • Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22(15):3003-15
  • Ravaud A, Hawkins R, Gardner JP, et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008;26(14):2285-91
  • Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25(29):4536-41
  • Rosenberg JE, Weinberg VK, Claros C, et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. J Clin Oncol 2008;26(20 Suppl):A5109
  • Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma clinical genitourinary. Cancer 2009;7(1):24-7
  • Feldman DR, Ginsberg MS, Baum M, et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):5100-
  • Cooney MM, Garcia JA, Elson P, et al. Sunitinib and bevacizumab in advanced solid tumors: a phase I trial. J Clin Oncol (Meeting Abstracts) 2008;26 (15 Suppl):3530
  • Fischer P, Patel P, Carducci MA, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):16020-
  • Motzer RJ, Hudes G, Wilding G, et al. Phase I trial of sunitinib malate plus interferon-α for patients with metastatic renal cell carcinoma. Clin Genitourinary Cancer 2009;7(1):28-33
  • Tsavachidou D, Tannir NM, Thomas C, et al. Reverse-phase protein array marker evaluation of protein expression patterns related to anti-angiogenesis treatment in renal cell carcinoma. J Clin Oncol 2008;26(20 Suppl):A16016
  • Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109(11):2257-67
  • Patel PH, Chadalavada RS, Ishill NM, et al. Hypoxia-inducible factor (HIF) 1-alpha and 2-alpha levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):5008
  • Negrier S, Gross-Goupil M, Perol D, et al. Analysis of characteristics in patients (pts) with metastatic renal cell cancer (MRCC) who achieved a prolonged benefit from sunitinib or sorafenib. J Clin Oncol (Meeting Abstracts)2008;26 (15 Suppl):16022
  • Wolter P, Stefan C, Decallonne B, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). J Clin Oncol (Meeting Abstracts)2008;26 (15 Suppl):5126
  • Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. [see comment]. J Clin Oncol 2008;26(33):5352-9
  • Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009;27(1):11-5
  • Thomas MB, Chadha R, Iwasaki M, et al. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):4567
  • Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44
  • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
  • Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23(16):3706-12
  • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
  • Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
  • Drug Interactions. Cytochrome P450 System. Available from: www.medicine.iupui.edu/flockhart/ [Cited 04 December 2008]
  • Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99(1):81-3
  • Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib induced hypothyroidism: a prospective evaluation. Br J Cancer 2008;99(3):448-54
  • Rosenbaum SE, Wu S, Newman MA, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008;16(6):557-66
  • Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J Clin Oncol 2007;25(18S (Suppl):A5011
  • Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19(11):1955-61
  • Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American college of cardiology/American heart association task force on practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society. Circulation 2005;112(12):e154-235
  • Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289(19):2560-72
  • Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008;112(11):2500-8
  • Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370(9604):2011-9
  • Witteles RM, Telli ML, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):9597-
  • Mustian KM, Morrow GR, Carroll JK, et al. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist 2007;12(Suppl 1):52-67
  • Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003;37(9):1276-86
  • Robert C, Soria J-C, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6(7):491-500
  • Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol 2008;108(3-5):261-6
  • Chaskis C, Sadones J, Michotte A, et al. A phase II trial of sunitinib in patients with recurrent high-grade glioma. J Clin Oncol (Meeting Abstracts) 2008;26 (15 Suppl):13001-

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.